Could small molecules be used in combination with biologics for inflammatory bowel disease?

被引:0
作者
D'Amico, Ferdinando [1 ,2 ,3 ]
Danese, Silvio [1 ,2 ]
Fiorino, Gionata [1 ,2 ]
机构
[1] IRCCS Osped San Raffaele, Gastroenterol & Endoscopy, Via Olgettina 60, Milan, Italy
[2] Univ Vita Salute San Raffaele, Via Olgettina 60, Milan, Italy
[3] Humanitas Univ, Dept Biomed Sci, Milan, Italy
关键词
JAK-inhibitors; biologics; dual therapy; inflammatory bowel disease; Crohn's disease; ulcerative colitis;
D O I
10.1080/1744666X.2022.2104713
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
引用
收藏
页码:991 / 993
页数:3
相关论文
共 18 条
  • [1] Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
    Ahmed, Waseem
    Galati, Jonathan
    Kumar, Anand
    Christos, Paul J.
    Longman, Randy
    Lukin, Dana J.
    Scherl, Ellen
    Battat, Robert
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (03) : E361 - E379
  • [2] Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease
    Alayo, Quazim A.
    Fenster, Marc
    Altayar, Osama
    Glassner, Kerri L.
    Llano, Ernesto
    Clark-Snustad, Kindra
    Patel, Anish
    Kwapisz, Lukasz
    Yarur, Andres J.
    Cohen, Benjamin L.
    Ciorba, Matthew A.
    Thomas, Deborah
    Lee, Scott D.
    Loftus, Edward V., Jr.
    Fudman, David, I
    Abraham, Bincy P.
    Colombel, Jean-Frederic
    Deepak, Parakkal
    [J]. CROHNS & COLITIS 360, 2022, 4 (01)
  • [3] [Anonymous], FDA APPROVES OZANIMO
  • [4] Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis
    Bonovas, Stefanos
    Fiorino, Gionata
    Allocca, Mariangela
    Lytras, Theodore
    Nikolopoulos, Georgios K.
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2016, 14 (10) : 1385 - +
  • [5] Paradoxical inflammation induced by anti-TNF agents in patients with IBD
    Cleynen, Isabelle
    Vermeire, Severine
    [J]. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2012, 9 (09) : 496 - 503
  • [6] Long-term safety of approved biologics for ulcerative colitis
    D'Amico, Ferdinando
    Parigi, Tommaso Lorenzo
    Bonovas, Stefanos
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    [J]. EXPERT OPINION ON DRUG SAFETY, 2020, 19 (07) : 807 - 816
  • [7] Defining difficult-to-treat inflammatory bowel disease: why and how
    Danese, Silvio
    Parigi, Tommaso Lorenzo
    Peyrin-Biroulet, Laurent
    Ghosh, Subrata
    [J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (07): : S20 - S22
  • [8] EMA, 2020, ZEP
  • [9] Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-α agents
    Fiorino, Gionata
    Danese, Silvio
    Pariente, Benjamin
    Allez, Matthieu
    [J]. AUTOIMMUNITY REVIEWS, 2014, 13 (01) : 15 - 19
  • [10] PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD
    Gilardi, Daniela
    Gabbiadini, Roberto
    Allocca, Mariangela
    Correale, Carmen
    Fiorino, Gionata
    Furfaro, Federica
    Zilli, Alessandra
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    [J]. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2020, 14 (09) : 797 - 806